کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5969507 | 1576175 | 2014 | 8 صفحه PDF | دانلود رایگان |

- Translation of cardioprotective agents into useful treatment is challenging.
- Right treatment, in the right patient at the right time will improve effectiveness.
- Trial design must reflect the rules of cardioprotection to demonstrate benefit.
Ischaemiaâreperfusion (IR) injury is an important cause of myocardial damage during percutaneous coronary intervention (PCI). There are few therapies in widespread clinical use which impact on IR injury and it remains an important and underutilized target for treatment in acute myocardial infarction. This review will examine the translational scientific evidence for ischaemic conditioning and pharmacological agents including conditioning mimetics such as cyclosporine, anti-inflammatory agents, and those which modify myocardial glucose metabolism. We will address the reasons why many trials have failed to demonstrate clinical benefit and emphasize the need to deliver the right therapy to the right patient, at the right time to achieve successful translation of cardioprotection from bench-to-bedside. We critique trial design and offer advice for future translational trials in the field to ensure that effective treatments can be demonstrated clinically to improve patient outcomes during PCI.
Journal: International Journal of Cardiology - Volume 177, Issue 3, 20 December 2014, Pages 786-793